Specify a stock or a cryptocurrency in the search bar to get a summary
Dyne Therapeutics Inc
DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Address: 1560 Trapelo Road, Waltham, MA, United States, 02451
Analytics
WallStreet Target Price
52.2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DYN
Dividend Analytics DYN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DYN
Stock Valuation DYN
Financials DYN
Results | 2019 | Dynamics |